Lineage Cell Therapeutics (LCTX) Total Liabilities (2010 - 2026)

Lineage Cell Therapeutics has reported Total Liabilities for 17 years, with the latest figure at $56.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 66.69% year-over-year to $56.8 million; the trailing twelve-month figure through Mar 2026 stood at $56.8 million (up 66.69% YoY), and the FY2025 full-year result was $69.2 million, up 91.23% from the prior year.
• Total Liabilities for Q1 2026 stood at $56.8 million, down from $69.2 million in the prior quarter.
• The five-year high for Total Liabilities was $69.2 million in Q4 2025, with the low at $31.8 million in Q3 2024.
• Historically, Total Liabilities has averaged $46.8 million across 5 years, with a median of $43.7 million in 2025.
• The largest YoY upside for Total Liabilities was 422.12% in 2022 against a maximum downside of 38.16% in 2022.
• Lineage Cell Therapeutics' Total Liabilities stood at $51.7 million in 2022, then decreased by 24.61% to $39.0 million in 2023, then fell by 7.15% to $36.2 million in 2024, then surged by 91.23% to $69.2 million in 2025, then decreased by 17.91% to $56.8 million in 2026.
• The last three Total Liabilities figures came in at $56.8 million (Q1 2026), $69.2 million (Q4 2025), and $68.8 million (Q3 2025), per Business Quant data.